β型人乳头瘤病毒致皮肤鳞状细胞癌机制的研究进展

国际肿瘤学杂志››2019,Vol. 46››Issue (12): 760-763.doi:10.3760/cma.j.issn.1673-422X.2019.12.011

β型人乳头瘤病毒致皮肤鳞状细胞癌机制的研究进展

马庆宇¹梁俊琴²

1 新疆医科大学研究生学院，乌鲁木齐 830054； 2 新疆维吾尔自治区人民医院皮肤科，乌鲁木齐 830000

收稿日期:2019-10-08修回日期:2019-11-08出版日期:2019-12-08发布日期:2019-12-09
通讯作者:梁俊琴 E-mail:zyeemail@163.com
基金资助:
国家自然科学基金（81760494）

Research progress on the mechanism of β human papillomavirus induced cutaneous squamous cell carcinoma

Ma Qingyu¹, Liang Junqin²

1 Graduate College of Xinjiang Medical University, Urumqi 830054, China; 2 Department of Dermatology, Xinjiang Uygur Autonomous Region People′s Hospital, Urumqi 830000, China

Received:2019-10-08Revised:2019-11-08Online:2019-12-08Published:2019-12-09
Contact:Liang Junqin E-mail:zyeemail@163.com
Supported by:
National Natural Science Foundation of China (81760494)

摘要/Abstract

摘要：人乳头瘤病毒（HPV）感染鳞状上皮，可诱发过度增生性病变，β型人乳头瘤病毒(β-HPV)是HPV根据L1蛋白核酸序列的不同分型中常见的一种。近年来皮肤鳞状细胞癌（CSCC）发病率增加，β-HPV可能参与了CSCC的发病，通过病毒E6和E7蛋白分别抑制p53和pRb抑癌基因，在癌症的起始环节起重要作用。因此，β-HPV是预防CSCC的靶点，特别是对于接受器官移植后免疫抑制的患者。

关键词:肿瘤,鳞状细胞,β乳头状瘤病毒属,机制

Abstract:Human papillomaviruse （HPV） infects squamous epithelium and induces hyperproliferative lesions. β human papillomavirus (β-HPV) is a common type of HPV according to the nucleic acid sequence of L1 protein. In recent years, the incidence of cutaneous squamous cell carcinoma (CSCC) has increased, βHPV may be involved in the pathogenesis of CSCC. Besides, β-HPV inhibits p53 and pRb tumor suppressor genes through virus E6 and E7 proteins, which plays an important role in the initial stage of cancer. Therefore, the β-HPV is a target for preventing CSCC, especially for patients with immunosuppression who have received organ transplantation.

Key words:Neoplasms, squamous cell,Betapapillomavirus,Mechanism

马庆宇, 梁俊琴. β型人乳头瘤病毒致皮肤鳞状细胞癌机制的研究进展[J]. 国际肿瘤学杂志, 2019, 46(12): 760-763.

Ma Qingyu, Liang Junqin. Research progress on the mechanism of β human papillomavirus induced cutaneous squamous cell carcinoma[J]. Journal of International Oncology, 2019, 46(12): 760-763.

参考文献［30］

［1］	Venuti A, Lohse S, Tommasino M, et al. Cross-talk of cutaneous beta human papillomaviruses and the immune system: determinants of disease penetrance［J］. Philos Trans R Soc Lond B Biol Sci, 2019, 374(1773): 20180287. DOI: 10.1098/rstb.2018.0287.
［2］	Sichero L, Rollison DE, Amorrortu RP, et al. Beta human papillomavirus and associated diseases［J］. Acta Cytol, 2019, 63(2): 100-108. DOI: 10.1159/000492659.
［3］	Rollison DE, Viarisio D, Amorrortu RP, et al. An emerging issue in oncogenic virology: the role of beta HPV types in development of cutaneous squamous cell carcinoma［J］. J Virol, 2019, 93(7). pii: e01003-18. DOI: 10.1128/jvi.01003-18.
［4］	Marx B, Miller-Lazic D, Doorbar J, et al. HPV8-E6 interferes with syntenin-2 expression through deregulation of differentiation, methylation and phosphatidylinositidekinase dependent mechanisms［J］. Front Microbiol, 2017, 8: 1724. DOI: 10.3389/fmicb.2017.01724.
［5］	Iannacone MR, Gheit T, Pfister H, et al. Case-control study of genus-beta human papillomaviruses in plucked eyebrow hairs and cutaneous squamous cell carcinoma［J］. Int J Cancer, 2014, 134(9): 2231-2244. DOI: 10.1002/ijc.28552.
［6］	Tommasino M. The biology of beta human papillomaviruses［J］. Virus Res, 2017, 231: 128-138. DOI: 10.1016/j.virusres.2016.11.013.
［7］	Brancaccio RN, Robitaille A, Dutta S, et al. Generation of a novel next-generation sequencing-based method for the isolation of new human papillomavirus types［J］. Virology, 2018, 520: 1-10. DOI: 10.1016/j.virol.2018.04.017.
［8］	Chahoud J, Semaan A, Chen Y, et al. Association between β-genus human papillomavirus and cutaneous squamous cell carcinoma in immunocompetent individuals-a meta-analysis［J］. JAMA Dermatol, 2016, 152(12): 1354-1364. DOI: 10.1001/jamadermatol.2015.4530.
［9］	Waldman A, Schmults C. Cutaneous squamous cell carcinoma［J］. Hematol Oncol Clin North Am, 2019, 33(1): 1-12. DOI: 10.1016/j.hoc.2018.08.001.
［10］	Hampras SS, Rollison DE, Giuliano AR, et al. Prevalence and concordance of cutaneous beta human papillomavirus infection at mucosal and cutaneous sites［J］. J Infect Dis, 2017, 216(1): 92-96. DOI: 10.1093/infdis/jix245.
［11］	Genders RE, Osinga JAJ, Tromp EE, et al. Metastasis risk of cutaneous squamous cell carcinoma in organ transplant recipients and immunocompetent patients［J］. Acta Derm Venereol, 2018, 98(6): 551-555. DOI: 10.2340/00015555-2901.
［12］	Chockalingam R, Downing C, Tyring SK. Cutaneous squamous cell carcinomas in organ transplant recipients［J］. J Clin Med, 2015, 4(6): 1229-1239. DOI: 10.3390/jcm4061229.
［13］	Bouwes Bavinck JN, Feltkamp MCW, Green AC, et al. Human papillomavirus and posttransplantation cutaneous squamous cell carcinoma: a multicenter, prospective cohort study［J］. Am J Transplant, 2018, 18(5): 1220-1230. DOI: 10.1111/ajt.14537.
［14］	Iannacone MR, Gheit T, Waterboer T, et al. Case-control study of cutaneous human papillomavirus infection in Basal cell carcinoma of the skin［J］. J Invest Dermatol, 2013, 133(6): 1512-1520. DOI: 10.1038/jid.2012.478.
［15］	Meyers JM, Grace M, Uberoi A, et al. Inhibition of TGF-β and NOTCH signaling by cutaneous papillomaviruses［J］. Front Microbiol, 2018, 9: 389. DOI: 10.3389/fmicb.2018.00389.
［16］	Viarisio D, Müller-Decker K, Accardi R, et al. Beta HPV38 oncoproteins act with a hit-and-run mechanism in ultraviolet radiation-induced skin carcinogenesis in mice［J］. PLOS Pathog, 2018, 14(1): e1006783. DOI: 10.1371/journal.ppat.1006783.
［17］	Gheit T. Mucosal and cutaneous human papillomavirus infections and cancer biology［J］. Front Oncol, 2019, 9: 355. DOI: 10.3389/fonc.2019.00355.
［18］	Yeo-Teh NSL, Ito Y, Jha S. High-risk human papillomaviral oncogenes E6 and E7 target key cellular pathways to achieve oncogenesis［J］. Int J Mol Sci, 2018, 19(6). pii: E1706. DOI: 10.3390/ijms19061706.
［19］	Martinez-Zapien D, Ruiz FX, Poirson J, et al. Structure of the E6/E6AP/p53 complex required for HPV-mediated degradation of p53［J］. Nature, 2016, 529(7587): 541-545. DOI: 10.1038/nature16481.
［20］	Steels A, Vannevel L, Zwaenepoel O, et al. Nb-induced stabilisation of p53 in HPV-infected cells［J］. Sci Rep, 2019, 9(1): 12680. DOI: 10.1038/s41598-019-49061-9.
［21］	Nyman PE, Buehler D, Lambert PF. Loss of function of canonical notch signaling drives head and neck carcinogenesis［J］. Clin Cancer Res, 2018, 24(24): 6308-6318. DOI: 10.1158/1078-0432.CCR-17-3535.
［22］	Estêvo D, Costa NR, Gil da Costa RM, et al. Hallmarks of HPV carcinogenesis: the role of E6, E7 and E5 oncoproteins in cellular malignancy［J］. Biochim Biophys Acta Gene Regul Mech, 2019, 1862(2): 153-162. DOI: 10.1016/j.bbagrm.2019.01.001.
［23］	Szalmás A, Tomai＇c V, Basukala O, et al. The PTPN14 tumor suppressor is a degradation target of human papillomavirus E7［J］. J Virol, 2017, 91(7). pii: e00057-17. DOI: 10.1128/JVI.00057-17.
［24］	Akgül B, Kirschberg M, Storey A, et al. Human papillomavirus type 8 oncoproteins E6 and E7 cooperate in downregulation of the cellular checkpoint kinase-1［J］. Int J Cancer, 2019, 145(3): 797-806. DOI: 10.1002/ijc.32223.
［25］	Heuser S, Hufbauer M, Steiger J, et al. The fibronectin/α3β1 integrin axis serves as molecular basis for keratinocyte invasion induced by βHPV［J］. Oncogene, 2016, 35(34): 4529-4539. DOI: 10.1038/onc.2015.512.
［26］	Hufbauer M, Cooke J, van der Horst GT, et al. Human papillomavirus mediated inhibition of DNA damage sensing and repair drives skin carcinogenesis［J］. Mol Cancer, 2015, 14: 183. DOI: 10.1186/s12943-015-0453-7.
［27］	Tommasino M. HPV and skin carcinogenesis［J］. Papillomavirus Res, 2019, 7: 129-131. DOI: 10.1016/j.pvr.2019.04.003.
［28］	Pacini L, Ceraolo MG, Venuti A, et al. UV radiation activates toll-like receptor 9 expression in primary human keratinocytes, an event inhibited by human papillomavirus 38 E6 and E7 oncoproteins［J］. J Virol, 2017, 91(19). pii: e01123-17. DOI: 10.1128/JVI.01123-17.
［29］	Dong W, Arpin C, Accardi R, et al. Loss of p53 or p73 in human papillomavirus type 38 E6 and E7 transgenic mice partially restores the UV-activated cell cycle checkpoints［J］. Oncogene, 2008, 27(20): 2923-2928. DOI: 10.1038/sj.onc.1210944.
［30］	Pacini L, Savini C, Ghittoni R, et al. Downregulation of toll-like receptor 9 expression by beta human papillomavirus 38 and implications for cell cycle control［J］. J Virol, 2015, 89(22): 11396-11405. DOI: 10.1128/JVI.02151-15.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲.血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华.Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青.血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺.PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云.新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚.EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六.基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东.ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅.基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳.炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝.癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志.宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.